Cassava Sciences Inc (SAVA)

[investingdog]

From .tube:
This is how low the bar is for approval:
Leqembi (lecanemab) was granted accelerated approval in January 2023 based on its ability to clear amyloid plaques in early Alzheimer's patients in Phase 3 trials.
Confirmatory trials were ongoing.
Aduhelm (aducanumab) received accelerated approval in June 2021, though its clinical benefit remains controversial due to mixed Phase 3 data.
The FDA converted Leqembi to full traditional approval in July 2023 after its confirmatory trials showed it slowed cognitive decline (no cog improvement, just slowed decline "*in 27% of it's patients**), an unprecedented achievement for an Alzheimer's drug...
So in addition to the safety concerns, like brain bleeding and death, ONLY 27% of the EARLY to MILD patients had their Alzheimer's rate of decline SLOWED or 73% receive ZERO positive benefits!
Now imagine if this drug shows anything close to the P2 data (47% cognitive improvement and 23% slowed decline over 12